Fortrea Holdings stock
FTRENASDAQFortrea Holdings Inc., HealthcareISIN US34965K1079
41Score 41 out of 100, Weak
Price and trend
66 / 100
Price history
+73% in one yearThe chart shows daily closes over 3 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 28% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 21% below its 52-week high. Largest decline in 3 years: 90% (April 2024 to May 2025).
Chart figures for advanced users
- SMA 50$20.70
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.87
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$8.87
- The lowest closing price of the last twelve months.
- Resistance$25.88
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Fortrea Holdings Inc. belongs to the Biotechnology industry (United States) and, with a market value of $1.93B, is number 136 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.72B (up 1% year on year) and a loss of $986.2M.
- For fiscal 2026, analysts expect on average revenue of $2.68B (down 1.6%) and adjusted earnings per share of $0.85 (up 102.9%).
Show more
- MEQIRI Score 41 out of 100 (Weak): rank 541 of 714 in Healthcare, median 53.
- Our model puts fair value at $20.41, with the price 0% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Analysts expect strong earnings growthUp 20.6% a year through 2028 (estimates from 7 analysts).
Weaknesses
- Loss-makingLoss of $68.7M over the last 12 months.Fundamentals 41
- High debtDebt 2.1 times equity (latest quarter), Biotechnology median 0.09.Stability 21
- Volatile share priceVolatility 68% a year over the last 12 months.Stability 21
Its standout strength is momentum, while stability and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 43 to 41.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- weak fundamentals
- price up very strongly over the past year
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $13.61 and expensive above $40.82 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 11.4%. At 12.4% the fair value would be $17.92, at 10.4% it would be $23.66.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue fell 3.4% on the twelve months before. Revenue has stayed largely stable since 2020.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 16%, operating −1%, net −36%. Last 12 months: net −3%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 29 Oct 2026EPS reported $0.28 (expected $0.22)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.85+0.9%
- Revenue
- $2.68B+0.6%
- Earnings per share
- $1.05−0.4%
- Revenue
- $2.76B+0.6%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −17.7%Fortrea raised its full year 2026 guidance midpoint for revenue and adjusted EBITDA while narrowing the ranges, now expecting revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million.
“We now expect full year revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 29 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 5 insiders sold, $4.37M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Russell Carrie ElizabethSale
9 Sept 2026, Interim CAO
- Shares
- 246
- Price
- $16.85
- Value
- $4,145
- Morais Mark A.Sale
9 Sept 2026, Chief Operating Officer
- Shares
- 3,149
- Price
- $16.85
- Value
- $53,061
- Morais Mark A.Sale
19 Aug 2026, Chief Operating Officer
- Shares
- 4,892
- Price
- $18.19
- Value
- $88,985
Show 5 more
- Thakral AnshulSale
6 Aug 2026, Chief Executive Officer
- Shares
- 111,857
- Price
- $18.11
- Value
- $2.03M
- Thakral AnshulSale
5 Aug 2026, Chief Executive Officer
- Shares
- 99,869
- Price
- $19.16
- Value
- $1.91M
- Sanders MachelleSale
3 Aug 2026, Board
- Shares
- 9,700
- Price
- $18.01
- Value
- $174,697
- Morais Mark A.Sale
10 Jun 2026, Chief Operating Officer
- Shares
- 4,674
- Price
- $16.82
- Value
- $78,617
- Parks RobertSale
18 May 2026, Chief Accounting Officer
- Shares
- 2,000
- Price
- $13.44
- Value
- $26,880
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Fortrea Holdings
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 41
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Harmony Biosciences HoldingsHRMY $2.01B73
- BioCryst PharmaceuticalsBCRX $1.97B37
- Agios PharmaceuticalsAGIO $1.96B40
- Zenas BioPharmaZBIO $1.95B38
- Kailera TherapeuticsKLRA $1.87B41
- Hemab Therapeutics HoldingsCOAG $1.84B47
- Stoke TherapeuticsSTOK $1.82B39
- Sarepta TherapeuticsSRPT $1.79B40
ETFs that hold Fortrea Holdings
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 0.19% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.13% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.11% | 0.30% | €2.28B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.10% | 0.30% | €185.82M |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.07% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.07% | 0.30% | €4.22B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.04% | 0.30% | €944.34M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.02% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.